The short version
The selected commercial descriptions agree on four advertised ingredients: GHK-Cu, BPC-157, TB-500 and KPV. One overview can cover that combination even when amounts or packaging differ. A blend supplies a fixed mixture; a stack may supply the ingredients separately. Read the exact contents rather than assuming the name specifies one universal formula.
A combination needs its own evaluation; ingredient evidence does not establish blend safety or benefit.
TB-500 naming can vary; check whether the preparation contains the short fragment or full-length thymosin beta-4. Understand the distinction ↗
Names you may see
Compound names, research identifiers, brand names and informal shorthand serve different purposes.
- KLOW
- Combination name · Here, the advertised GHK-Cu, BPC-157, TB-500 and KPV combination; no universal proportion or verified product identity implied.
- Klow Blend (GHK-CU, KPV, BPC-157, TB-500)
- Recorded name variation · A name associated with this entry; check exact ingredient, modification, formulation and context.
- K-L-O-W
- Recorded name variation · A name associated with this entry; check exact ingredient, modification, formulation and context.
- KLOW (BPC-157, KPV, TB-500, GHK-Cu) Blend
- Recorded name variation · A name associated with this entry; check exact ingredient, modification, formulation and context.
Similar names do not establish identical ingredients, molecular variants, product quality or interchangeable preparations. A blend nickname may describe different formulas.
Things worth checking
Are the ingredients unclear, or just the proportions?
The checked listings name the same four ingredients. Both advertise an example with GHK-Cu 50 mg and BPC-157, TB-500 and KPV 10 mg each, totaling 80 mg per vial. These are advertised vial contents, not a recommended dose or an independently validated optimum. Other presentations need their own contents checked.
Commercially advertised composition · not dosing guidance · Commercial ingredient description ↗
Does separate ingredient research prove the blend works better?
No. Combining ingredients creates separate questions about interactions, stability and outcomes. Four ingredient pages are useful background; they are not four trials of KLOW, and they do not establish an ideal ratio.
Ingredient-versus-combination evidence distinction · FDA TB-500 identity and evidence context; not a KLOW trial ↗
Questions to bring to a clinician or pharmacist
- Which findings apply to my goal and medical history?
- Could my medicines, supplements, or other compounds change the assessment?
- What monitoring, if any, would inform a decision—and what symptoms would need evaluation?
Monitoring is individual. Normal bloodwork does not establish that a compound or preparation is safe.
Clinical research
Ingredient studies do not establish the effects of this four-component mixture. No human trial of the exact KLOW combination is summarized here. This is a statement about our current coverage, not a claim that a comprehensive search found no research.
Research terms in everyday language ↗
Selected commercial descriptions establish how the name is used, not verified product contents or treatment results. Ingredient pages link their own research. A comprehensive search and appraisal of exact-combination studies have not been completed.
Read findings in the context of the exact product or preparation, the people studied, and the outcome measured. These draft profiles are starting points, rather than complete systematic reviews.
Community research
Structured community reports can help identify questions worth studying. They are considered separately from controlled studies, with their limitations kept visible.
No community reports published yet.
This profile has no published community dataset. We do not infer a trend or a benefit from missing reports.
How community research will work ↗What we will document about community advice
- The advice
- What people recommend, with dated sources and the scope of the discussions examined.
- The reasoning
- Why contributors believe it helps, without treating that explanation as an established mechanism.
- The evidence
- What supports the claim, contradicts it, or has not been tested.
- The cautions
- Possible downsides, conflicting experiences, and questions for a clinician or pharmacist.
No recommendation or community consensus is established by this framework. Descriptions of how common advice is will need documented source coverage.
A closer look
- Classification
- Advertised four-component combination; ingredient research is separate from combination evidence.
- Name variations
- Names you may see and important distinctions
- Source type
- Commercial composition descriptions and ingredient-level regulatory context
- Reference jurisdiction
- Commercial naming; United States ingredient-level regulatory context
Interpret the source in the context of the preparation and route it discusses. A regulatory notice and a controlled clinical trial answer different questions.
Read about each ingredient
Ghk-cu · Bpc-157 · Tb-500 · Kpv
These links describe ingredients individually, not evidence for the combination.
This first design edition reserves space for study-by-study summaries, definitions, and technical references as each profile receives editorial review.
Go to the source
Study cards identify whether the summary uses an abstract, full text, or an agency assessment. Follow the linked sources for their original context.
Source reference · Checked 8 November 2026 · Opens in a new tab
Commercial listing used only to document the ingredient names and example vial contents. Not a supplier assessment, endorsement or clinical study.
Commercial listing used to check contents, blend/stack packaging and the TB-500 naming inconsistency. Not independently verified product evidence.
For athletes: competition rules are a separate check ↗